Literature DB >> 27687305

Is the routine use of trimodality therapy for selected patients with non-small cell lung cancer supported by long-term clinical outcomes?

C Dickhoff1,2, K J Hartemink3, J Kooij1, P M van de Ven4, M A Paul2, E F Smit5,6, M Dahele7.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 27687305     DOI： 10.1093/annonc/mdw449

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  2 in total

Review 1.  Salvage surgery for recurrent or persistent tumour after radical (chemo)radiotherapy for locally advanced non-small cell lung cancer: a systematic review.

Authors:  Chris Dickhoff; Rene H J Otten; Martijn W Heymans; Max Dahele
Journal:  Ther Adv Med Oncol       Date:  2018-10-05       Impact factor: 8.168

2.  Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable T3-4N0-1 non-small cell lung cancer: the INCREASE trial.

Authors:  Chris Dickhoff; Suresh Senan; Famke L Schneiders; Joris Veltman; Sayed Hashemi; Johannes M A Daniels; Marieke Fransen; David J Heineman; Teodora Radonic; Peter M van de Ven; Imke H Bartelink; Lilian J Meijboom; Juan J Garcia-Vallejo; Daniela E Oprea-Lager; Tanja D de Gruijl; Idris Bahce
Journal:  BMC Cancer       Date:  2020-08-14       Impact factor: 4.430
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.